Cargando…

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients

PURPOSE: The objectives of this study were to assess the potential value of Ki-67 in predicting response to neoadjuvant chemotherapy in breast cancer patients and to suggest a reasonable cutoff value for classifying Ki-67 expression. METHODS: This study included 74 breast cancer patients who underwe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Kwan Il, Lee, Kyung Hee, Kim, Tae Ryung, Chun, Yong Soon, Lee, Tae Hoon, Park, Heung Kyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Breast Cancer Society 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3988341/ https://www.ncbi.nlm.nih.gov/pubmed/24744796 http://dx.doi.org/10.4048/jbc.2014.17.1.40

Ejemplares similares

Predictive Significance of p53, Ki-67, and Bcl-2 Expression for Pathologic Complete Response after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Kim, Taeryung, et al.
Publicado: (2015)

Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy
por: Kim, Ji-Yeon, et al.
Publicado: (2022)

Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
por: Fasching, Peter A, et al.
Publicado: (2011)

Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer
por: LIN, QI, et al.
Publicado: (2013)

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer
por: Burcombe, R J, et al.
Publicado: (2005)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Can Ki-67 Play a Role in Prediction of Breast Cancer Patients' Response to Neoadjuvant Chemotherapy?
por: Ingolf, Juhasz-Böss, et al.
Publicado: (2014)

Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy
por: Ács, Balázs, et al.
Publicado: (2017)

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer
por: Burcombe, Russell, et al.
Publicado: (2006)

Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma
por: Jeong, Tae-Dong, et al.
Publicado: (2016)

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
por: Chen, Rui, et al.
Publicado: (2018)

Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
por: Prihantono, Prihantono, et al.
Publicado: (2017)

Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers
por: Srivastava, Pooja, et al.
Publicado: (2022)

The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy
por: Elmahs, Aya, et al.
Publicado: (2022)

Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
por: Silva, Leonardo Roberto da, et al.
Publicado: (2019)

Molecular subtyping of ependymoma and prognostic impact of Ki-67
por: Lim, Ka Young, et al.
Publicado: (2021)

Value of Breast Cancer Molecular Subtypes and Ki67 Expression for the Prediction of Efficacy and Prognosis of Neoadjuvant Chemotherapy in a Chinese Population
por: Wang, Jiayu, et al.
Publicado: (2016)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014
por: Moazed, Vahid, et al.
Publicado: (2018)

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
por: Ding, Yuqin, et al.
Publicado: (2020)

Breast Cancer–Related Lymphedema after Neoadjuvant Chemotherapy
por: Kim, Myungsoo, et al.
Publicado: (2015)

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011)

Ki67 Antigen as a Predictive Factor for Prognosis of Sinonasal Mucosal Melanoma
por: Kim, Dong-Kyu, et al.
Publicado: (2008)

The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
por: Zhang, Ailin, et al.
Publicado: (2021)

Prognostically Distinctive Subgroup in Pathologic N3 Breast Cancer
por: Kim, Yun Yeong, et al.
Publicado: (2016)

Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki67 in Chinese breast cancer patients: A retrospective study of 525 patients
por: Wu, Yu-tuan, et al.
Publicado: (2018)

Decrease in the Ki67 index during neoadjuvant chemotherapy predicts favorable relapse-free survival in patients with locally advanced breast cancer
por: Chen, Chunfa, et al.
Publicado: (2019)

Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
por: Pistelli, Mirco, et al.
Publicado: (2021)

Nomogram for Predicting Breast Conservation after Neoadjuvant Chemotherapy
por: Kim, Min Kyoon, et al.
Publicado: (2015)

Interobserver Variability of Ki-67 Measurement in Breast Cancer
por: Chung, Yul Ri, et al.
Publicado: (2016)

VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma
por: Park, Seongyeol, et al.
Publicado: (2016)

Clinical Significance of Ki-67 Labeling Index in Pituitary Macroadenoma
por: Paek, Kyung-Il, et al.
Publicado: (2005)

Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group
por: Nielsen, Torsten O, et al.
Publicado: (2020)

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
por: Kim, Hee Kyung, et al.
Publicado: (2017)

Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer
por: Gianni, Luca, et al.
Publicado: (2022)

Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
por: Tao, Miaomiao, et al.
Publicado: (2017)

Ki-67 labeling index as a prognostic marker in advanced stomach cancer
por: Seo, Sang Hyuk, et al.
Publicado: (2019)

Prognostic Value of the Nodal Ratio and Ki-67 Expression in Breast Cancer Patients Treated with Postmastectomy Radiotherapy
por: Koo, Tae Ryool, et al.
Publicado: (2013)

Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer
por: LI, HAITAO, et al.
Publicado: (2015)

Expression of Cyclooxygenase-2, p53 and Ki-67 in Gastric Cancer
por: Joo, Young-Eun, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_sdt729163d5l91vlm35ucgl2em